SG10202010429YA - Targeting of cytokine antagonists - Google Patents

Targeting of cytokine antagonists

Info

Publication number
SG10202010429YA
SG10202010429YA SG10202010429YA SG10202010429YA SG10202010429YA SG 10202010429Y A SG10202010429Y A SG 10202010429YA SG 10202010429Y A SG10202010429Y A SG 10202010429YA SG 10202010429Y A SG10202010429Y A SG 10202010429YA SG 10202010429Y A SG10202010429Y A SG 10202010429YA
Authority
SG
Singapore
Prior art keywords
targeting
cytokine antagonists
cytokine
antagonists
Prior art date
Application number
SG10202010429YA
Inventor
Jan Tavernier
Lennart Zabeau
Gilles Uzé
Franciane Paul
Yann Bordat
Geneviève Garcin
Original Assignee
Vib Vzw
Univ Gent
Centre Nat Rech Scient
Univ Montpellier
Centre Hospitalier Regional Univ De Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vib Vzw, Univ Gent, Centre Nat Rech Scient, Univ Montpellier, Centre Hospitalier Regional Univ De Montpellier filed Critical Vib Vzw
Publication of SG10202010429YA publication Critical patent/SG10202010429YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/56IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
SG10202010429YA 2013-07-19 2014-07-01 Targeting of cytokine antagonists SG10202010429YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13306045 2013-07-19

Publications (1)

Publication Number Publication Date
SG10202010429YA true SG10202010429YA (en) 2020-11-27

Family

ID=48874233

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202010429YA SG10202010429YA (en) 2013-07-19 2014-07-01 Targeting of cytokine antagonists
SG11201600165WA SG11201600165WA (en) 2013-07-19 2014-07-01 Targeting of cytokine antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201600165WA SG11201600165WA (en) 2013-07-19 2014-07-01 Targeting of cytokine antagonists

Country Status (11)

Country Link
US (5) US9732135B2 (en)
EP (1) EP3022230B1 (en)
JP (1) JP6475712B2 (en)
KR (1) KR102305608B1 (en)
CN (1) CN105658669A (en)
AU (1) AU2014292355B2 (en)
CA (1) CA2918119C (en)
IL (1) IL243459B (en)
MX (1) MX2016000721A (en)
SG (2) SG10202010429YA (en)
WO (1) WO2015007520A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6416628B2 (en) * 2012-01-20 2018-10-31 ブイアイビー ブイゼットダブリュVib Vzw Targeted variant alpha helix bundle cytokine
CN105658669A (en) * 2013-07-19 2016-06-08 弗拉芒区生物技术研究所 Targeting of cytokine antagonists
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
CN109071632B (en) 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 Targeted therapeutic agents and uses thereof
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
US20190077871A1 (en) * 2016-03-07 2019-03-14 Vib Vzm Cd20 binding agents and uses thereof
EP3454887B1 (en) 2016-05-13 2021-01-20 Orionis Biosciences BV Targeted mutant interferon-beta and uses thereof
EP3455245A2 (en) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
CA3040802A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
WO2018144999A1 (en) 2017-02-06 2018-08-09 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
WO2018141964A1 (en) 2017-02-06 2018-08-09 Orionis Biosciences Nv Targeted chimeric proteins and uses thereof
EP3580230A1 (en) 2017-02-07 2019-12-18 VIB vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
EP3665201A4 (en) * 2017-08-09 2021-06-02 Orionis Biosciences, Inc. Cd8 binding agents
US11498966B2 (en) 2017-08-09 2022-11-15 Orionis Biosciences Inc. PD-1 and PD-L1 binding agents
EP3749295A4 (en) 2018-02-05 2022-04-27 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
CN111499718B (en) * 2019-01-30 2022-06-14 复旦大学 Human alpha interferon receptor binding related site mutant and application thereof
JP2022534837A (en) 2019-03-28 2022-08-04 オリオニス バイオサイエンシズ,インコーポレイテッド therapeutic interferon alpha 1 protein
MX2022000742A (en) 2019-07-18 2022-02-14 Enyo Pharma Method for decreasing adverse-effects of interferon.
EP4313312A1 (en) 2021-03-26 2024-02-07 Innate Pharma Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
BR112023025331A2 (en) 2021-06-09 2024-02-27 Innate Pharma MULTI-SPECIFIC PROTEIN, PHARMACEUTICAL COMPOSITION, RECOMBINANT CELL, NUCLEIC ACID OR NUCLEIC ACID SET, USE OF A PROTEIN OR COMPOSITION, METHODS OR USE
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
WO2024040247A1 (en) 2022-08-18 2024-02-22 Regeneron Pharmaceuticals, Inc. Interferon proproteins and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69007975T2 (en) 1989-08-22 1994-07-21 Immunex Corp FUSION PROTEIN CONSISTING OF GM-CSF AND IL-3.
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
WO1997041232A1 (en) * 1996-04-26 1997-11-06 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
HUP0202442A3 (en) * 1999-08-09 2005-01-28 Lexigen Pharmaceuticals Corp L Multiple cytokine-antibody complexes
US20020193569A1 (en) * 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
CA2585549A1 (en) 2004-11-18 2006-05-26 Vib Vzw Novel type leptin receptor antagonist
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
EA014157B1 (en) * 2005-06-29 2010-10-29 Йеда Рисерч Энд Дивелопмент Ко. Лтд. RECOMBINANT INTERFERON α2 (IFNα2) MUTANTS
CA2693326A1 (en) 2006-08-02 2008-02-07 Mcgill University Gm-csf and il-15 fusokines and methods for modulation of the immune response
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
CA2690825C (en) * 2007-05-11 2019-02-12 Altor Bioscience Corporation Fusion molecules and il-15 variants
US20110038865A1 (en) 2007-06-26 2011-02-17 University Of Miami Antibody- endostatin fusion protein and its variants
MX349306B (en) * 2007-09-21 2017-07-19 Univ California Targeted interferon demonstrates potent apoptotic and anti-tumor activities.
US20110224407A1 (en) * 2008-09-09 2011-09-15 University Of Medicine And Dentistry Of New Jersey Type I Interferon Antagonists
WO2010036918A2 (en) 2008-09-26 2010-04-01 University Of Massachusetts Intracellular dna receptor
US20110294983A1 (en) 2008-12-08 2011-12-01 Complix Nv Single-chain antiparallel coiled coil proteins
EP2467165B1 (en) 2009-08-17 2015-01-07 Roche Glycart AG Targeted immunoconjugates
CN102497885A (en) 2009-09-10 2012-06-13 赛托斯生物技术公司 Use of interleukin-1 beta mutein conjugates in the treatment of diabetes
EP2718457A4 (en) 2011-06-06 2014-12-24 Immungene Inc Engineered antibody-tnfsf member ligand fusion molecules
WO2013059885A2 (en) * 2011-10-28 2013-05-02 Cephalon Australia Pty Ltd Polypeptide constructs and uses thereof
JP6416628B2 (en) 2012-01-20 2018-10-31 ブイアイビー ブイゼットダブリュVib Vzw Targeted variant alpha helix bundle cytokine
ES2800426T3 (en) 2012-03-03 2020-12-30 Immungene Inc Modified Interferon Antibody-Mutant Fusion Molecules
CN105658669A (en) * 2013-07-19 2016-06-08 弗拉芒区生物技术研究所 Targeting of cytokine antagonists

Also Published As

Publication number Publication date
US20210238247A1 (en) 2021-08-05
SG11201600165WA (en) 2016-02-26
AU2014292355B2 (en) 2019-08-01
US20180334489A1 (en) 2018-11-22
KR20160108292A (en) 2016-09-19
MX2016000721A (en) 2016-09-07
EP3022230A1 (en) 2016-05-25
CA2918119C (en) 2022-11-29
US9732135B2 (en) 2017-08-15
US20160159875A1 (en) 2016-06-09
JP2016529232A (en) 2016-09-23
US20180334488A1 (en) 2018-11-22
US10072059B2 (en) 2018-09-11
CN105658669A (en) 2016-06-08
JP6475712B2 (en) 2019-02-27
US20180057555A1 (en) 2018-03-01
WO2015007520A1 (en) 2015-01-22
IL243459B (en) 2019-10-31
CA2918119A1 (en) 2015-01-22
EP3022230B1 (en) 2019-11-06
AU2014292355A1 (en) 2016-02-04
IL243459A0 (en) 2016-03-31
US10947288B2 (en) 2021-03-16
KR102305608B1 (en) 2021-09-28

Similar Documents

Publication Publication Date Title
IL243459A0 (en) Targeting of cytokine antagonists
IL287516A (en) Therapeutic uses of empagliflozin
HRP20190101T1 (en) Therapeutic uses of empagliflozin
HK1218547A1 (en) Novel quinazolinones as bromodomain inhibitors
HK1213818A1 (en) Therapeutic uses of empagliflozin
SG11201601493UA (en) Atomizer
HRP20181710T1 (en) Use of benzimidazole-proline derivatives
EP4005604C0 (en) Delivery of drugs
RS58097B1 (en) Therapeutic uses of empagliflozin
HK1222339A1 (en) Inhibitors of metallo-ss-lactamase-enzymes --
HUP1300139A2 (en) Phenoxypiperidine h3 antagonists
ZA201602831B (en) Use of lactones
IL244537A0 (en) Novel delivery compositions and methods of using same
PL3049378T3 (en) Preparation of radioiodinated 3-fluoropropyl-nor-beta-cit
GB201319437D0 (en) Delivery of drugs
GB201318284D0 (en) Construction of surfaces
PL3071575T3 (en) Preparation of normorphinans
TWM475821U (en) Structure of mosquito-catch
TWM475524U (en) Structure of rivet-pulling
GB201304608D0 (en) BenTime of Yisrael operable arrangement
TWM475672U (en) Improved structure of signage